Imtiaz Ahmed, MD
Internal Medicine · Springfield, OHNPI 1619986155
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 476 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 11.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,111 and has fallen 99.2% since, to $17 in 2024. Among internal medicine clinicians in OH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 476 payments — averaging $12.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$724
- Pfizer$713
- Amarin Pharma, Inc.$640
- AbbVie$587
- GSK$481
- Novo Nordisk$460
- plus $2K from 25 others
What the payments were for
- Food & beverage$6,076100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 33 | $724 |
| Pfizer | 76 | $713 |
| Amarin Pharma, Inc. | 47 | $640 |
| AbbVie(2 entities) | 44 | $587 |
| GSK | 48 | $481 |
| Novo Nordisk | 49 | $460 |
| Merck | 27 | $382 |
| Amgen | 20 | $284 |
| Sunovion Pharmaceuticals Inc. | 25 | $283 |
| Lilly USA, LLC | 19 | $248 |
| Boehringer Ingelheim | 16 | $211 |
| Astellas Pharma US Inc | 11 | $162 |
| Biohaven Pharmaceuticals, Inc. | 16 | $148 |
| Novartis | 8 | $128 |
| Bayer | 3 | $96 |
| Johnson & Johnson | 6 | $82 |
| Sanofi-aventis U.S. LLC | 5 | $74 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $61 |
| Kowa Pharmaceuticals America, Inc. | 4 | $59 |
| Boston Scientific | 1 | $35 |
| Supernus Pharmaceuticals, Inc. | 2 | $34 |
| E.r. Squibb & Sons, L.L.C. | 2 | $26 |
| Otsuka America Pharmaceutical, Inc. | 1 | $26 |
| Scilex Pharmaceuticals Inc. | 2 | $24 |
| Daiichi Sankyo Inc. | 1 | $23 |
| Grifols USA, LLC | 1 | $18 |
| Averitas Pharma Inc. | 1 | $17 |
| Avanir Pharmaceuticals, Inc. | 1 | $17 |
| Hikma Pharmaceuticals USA | 1 | $14 |
| Sun Pharmaceutical Industries Inc. | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,082 in reported general payments places this provider in the 90th percentile of 4,428 internal medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 169 | $149,740 |
| JardianceEmpagliflozin | 92 | $106,087 |
| FarxigaDapagliflozin Propanediol | 84 | $86,480 |
| JanuviaSitagliptin Phosphate | 67 | $72,250 |
| Droxidopa | 13 | $70,044 |
| TrulicityDulaglutide | 37 | $47,489 |
| Spiriva RespimatTiotropium Bromide | 60 | $43,094 |
| OzempicSemaglutide | 18 | $30,286 |
| JanumetSitagliptin Phos/Metformin Hcl | 23 | $26,996 |
| Tresiba Flextouch U-100Insulin Degludec | 29 | $25,676 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 32 | $25,295 |
| MyrbetriqMirabegron | 32 | $25,100 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 40 | $24,975 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 30 | $19,203 |
| TradjentaLinagliptin | 24 | $17,862 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Spiriva Respimat, Tradjenta | $211 | $167,043176 claims |
| PfizerEliquis | $713 | $149,740169 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort, Nexium | $724 | $130,388185 claims |
| MerckJanuvia, Janumet | $382 | $99,24690 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $481 | $60,20589 claims |
| Lilly USA, LLCTrulicity | $248 | $47,48937 claims |
| Novo NordiskOzempic | $460 | $30,28618 claims |
| Astellas Pharma US IncMyrbetriq | $162 | $25,10032 claims |
| AbbVieLinzess | $587 | $13,73020 claims |
| Johnson & JohnsonXarelto | $82 | $11,69813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,428 internal medicine providers in Ohio.
Other internal medicine in Springfield
- Hassan MalikAkron$1.7M
- Cyrus HarrisCleveland$726K
- Nina DeepWesterville$614K
- Necklall KhooblallAustintown$448K
- Daniel WeissMentor$406K
- Richard KimDayton$326K
- Marina MagreyCleveland$312K
- Lisa LarkinCincinnati$276K
- Gregg FaimanMayfield Hts$274K
- Vincent MartinCincinnati$261K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.